FluLaval

ApprovedBiologic

NNational Heart, Lung, and Blood Institute (NHLBI)

FluLaval is one of 52 biologic programs targeting Lymphoma. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphomaRecruiting

InfluenzaActive, not recruiting

LymphomaApproved

Recruiting

InfluenzaPreclinical

Active, not recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

FluLaval

NNational Heart, Lung, and Blood Institute (NHLBI)

Approved

1 2

Velban

EEastern Cooperative Oncology Group

Preclinical

15 3

Oncaspar

SServier

Preclinical

15 4

Zofran

Novartis

Preclinical

2 5

Norvir

AbbVie

Preclinical

1 6

Wellcovorin

GGlaxo Dba Glaxosmithkline

Preclinical

4 7

Tafasitamab

Incyte

Preclinical

7 8

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 9

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 10

Nuvigil

NNuvo Research GmbH

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

ApprovedRecruiting

Lymphoma

NCT05170399

Clinical

Trials by Indication[1]

Influenza1 trial

Immune Responses Induced by Different Licensed Influenza Vaccines

Completed·UUniversity of Massachusetts, Worcester·N/A·NCT00902278·193 enrolled

Lymphoma1 trial

Vaccine Responses in Patients With B Cell Malignancies

Recruiting·NNational Heart, Lung, and Blood Institute (NHLBI)·Approved·NCT05170399·350 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for FluLaval. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — FluLaval compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for FluLaval. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Heart, Lung, and Blood Institute (NHLBI) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Approved[1]
Company: NNational Heart, Lung, and Blood Institute (NHLBI)

FluLaval

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Trials by Indication[1]

Influenza1 trial

Lymphoma1 trial

References

Drug Info

Quick Facts

Related News